Hutchmed begins phase-three trials of lymphoma therapy in China
(Alliance News) - Hutchmed China Ltd on Monday said it had begun phase-three clinical trials of its lymphoma treatment in China. Read More
| Price | 203.00p on 24-03-2026 at 19:35:12 |
|---|---|
| Change | -2.00p -0.98% |
| Buy | 212.00p |
| Sell | 204.00p |
| Last Trade: | Sell 32.00 at 203.00p |
| Day's Volume: | 18,135 |
| Last Close: | 203.00p |
| Open: | 203.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 201.00p - 212.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.74b |
| VWAP: | 200.19047p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 32 | 203.00p | Uncrossing Trade |
16:35:24 - 24-Mar-26 |
| Buy* | 107 | 212.00p | Automatic Execution |
16:29:53 - 24-Mar-26 |
| Sell* | 240 | 204.00p | Automatic Execution |
16:13:06 - 24-Mar-26 |
| Buy* | 11 | 210.00p | Ordinary |
15:14:22 - 24-Mar-26 |
| Buy* | 1,200 | 203.00p | Automatic Execution |
14:39:42 - 24-Mar-26 |
| Buy* | 2 | 203.00p | SI Trade |
14:25:42 - 24-Mar-26 |
| Sell* | 76 | 201.00p | Automatic Execution |
14:25:42 - 24-Mar-26 |
| Buy* | 150 | 203.00p | Automatic Execution |
14:12:50 - 24-Mar-26 |
| Buy* | 5 | 203.00p | SI Trade |
14:12:50 - 24-Mar-26 |
| Buy* | 150 | 203.00p | Automatic Execution |
14:12:50 - 24-Mar-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 23rd Mar 2026 7:00 am | RNS-R | HUTCHMED Initiates Phase III Trial of HMPL-760 |
| 16th Mar 2026 8:30 am | RNS | Vesting of awards under Long Term Incentive Plan |
| 16th Mar 2026 8:30 am | RNS | Vesting of awards under Long Term Incentive Plan |
| 11th Mar 2026 8:30 am | RNS | Vesting of awards under Long Term Incentive Plan |
| 11th Mar 2026 8:30 am | RNS | Vesting of awards under Long Term Incentive Plan |
| 9th Mar 2026 9:30 am | RNS | Update on Licensed Oncology Product in China |
| 6th Mar 2026 8:30 am | RNS | Directorate change |
| 5th Mar 2026 1:00 pm | RNS-R | Publication of Form 20-F |
| 5th Mar 2026 11:00 am | RNS | 2025 Full Year Results and Business Updates |
| 4th Mar 2026 8:30 am | RNS-R | HUTCHMED Initiates Global Trial of ATTC Candidate |